A comprehensive prognostic stratification for patients with metastatic renal clear cell carcinoma

Kang Su Cho, Young Deuk Choi, Se Joong Kim, Chun Il Kim, Byung Ha Chung, Do Hwan Seong, Dong Hyeon Lee, Jin Seon Cho, In Rae Cho, Sung Joon Hong

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Purpose: To develop a reliable prognostic model for patients with metastatic renal cell carcinoma (RCC) based on features readily available in common clinical settings. Patients and Methods: A total of 197 patients with RCC who underwent nephrectomy and immunotherapy from 1995 to 2004 were retrospectively reviewed. Their mean age was 55.1 ± 11.8 yrs (24-83 yrs) and mean survival time from metastasis was 22.6 ± 20.2 mos (3-120 mos). The impact of 24 clinicopathological features on disease specific survival was investigated. Results: On univariate analysis, constitutional symptoms, sarcomatoid differentiation, tumor necrosis, multiple primary lesions, liver metastasis, Eastern Cooperative Oncology Group Performance Status (ECOG-PS), thrombocytosis, alkaline pbosphatase, hematocrit, T stage, N stage, and nuclear grade had significant influence on survival (p < 0.05). Multivariate analysis revealed the following features associated with survival: sarcomatoid differentiation [hazard ratio (HR)=2.99, p<0.001], liver metastasis (HR = 2.09, p = 0.002), ECOG-PS (HR = 1.95, p = 0.005), N stage (HR = 1.94, p = 0.002), and number of metastatic sites (HR = 1.76, p = 0.003). An individual prognostic score was defined as the sum of the weight of these features. According to prognostic scores, patients could be subdivided into 3 groups: low risk (score 0), intermediate risk (score 1 or 2), and high risk (score ≥ 3). Conclusion: A comprehensive prognostic stratification model was developed to predict survival and stratify patients for prospective clinical trials.

Original languageEnglish
Pages (from-to)451-458
Number of pages8
JournalYonsei medical journal
Volume49
Issue number3
DOIs
Publication statusPublished - 2008 Jun 1

Fingerprint

Renal Cell Carcinoma
Survival
Neoplasm Metastasis
Thrombocytosis
Liver
Nephrectomy
Hematocrit
Immunotherapy
Necrosis
Multivariate Analysis
Survival Rate
Clinical Trials
Weights and Measures
Neoplasms

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Cho, Kang Su ; Choi, Young Deuk ; Kim, Se Joong ; Kim, Chun Il ; Chung, Byung Ha ; Seong, Do Hwan ; Lee, Dong Hyeon ; Cho, Jin Seon ; Cho, In Rae ; Hong, Sung Joon. / A comprehensive prognostic stratification for patients with metastatic renal clear cell carcinoma. In: Yonsei medical journal. 2008 ; Vol. 49, No. 3. pp. 451-458.
@article{55a6d33a92f84b348d8bf2c259e573a8,
title = "A comprehensive prognostic stratification for patients with metastatic renal clear cell carcinoma",
abstract = "Purpose: To develop a reliable prognostic model for patients with metastatic renal cell carcinoma (RCC) based on features readily available in common clinical settings. Patients and Methods: A total of 197 patients with RCC who underwent nephrectomy and immunotherapy from 1995 to 2004 were retrospectively reviewed. Their mean age was 55.1 ± 11.8 yrs (24-83 yrs) and mean survival time from metastasis was 22.6 ± 20.2 mos (3-120 mos). The impact of 24 clinicopathological features on disease specific survival was investigated. Results: On univariate analysis, constitutional symptoms, sarcomatoid differentiation, tumor necrosis, multiple primary lesions, liver metastasis, Eastern Cooperative Oncology Group Performance Status (ECOG-PS), thrombocytosis, alkaline pbosphatase, hematocrit, T stage, N stage, and nuclear grade had significant influence on survival (p < 0.05). Multivariate analysis revealed the following features associated with survival: sarcomatoid differentiation [hazard ratio (HR)=2.99, p<0.001], liver metastasis (HR = 2.09, p = 0.002), ECOG-PS (HR = 1.95, p = 0.005), N stage (HR = 1.94, p = 0.002), and number of metastatic sites (HR = 1.76, p = 0.003). An individual prognostic score was defined as the sum of the weight of these features. According to prognostic scores, patients could be subdivided into 3 groups: low risk (score 0), intermediate risk (score 1 or 2), and high risk (score ≥ 3). Conclusion: A comprehensive prognostic stratification model was developed to predict survival and stratify patients for prospective clinical trials.",
author = "Cho, {Kang Su} and Choi, {Young Deuk} and Kim, {Se Joong} and Kim, {Chun Il} and Chung, {Byung Ha} and Seong, {Do Hwan} and Lee, {Dong Hyeon} and Cho, {Jin Seon} and Cho, {In Rae} and Hong, {Sung Joon}",
year = "2008",
month = "6",
day = "1",
doi = "10.3349/ymj.2008.49.3.451",
language = "English",
volume = "49",
pages = "451--458",
journal = "Yonsei Medical Journal",
issn = "0513-5796",
publisher = "Yonsei University College of Medicine",
number = "3",

}

A comprehensive prognostic stratification for patients with metastatic renal clear cell carcinoma. / Cho, Kang Su; Choi, Young Deuk; Kim, Se Joong; Kim, Chun Il; Chung, Byung Ha; Seong, Do Hwan; Lee, Dong Hyeon; Cho, Jin Seon; Cho, In Rae; Hong, Sung Joon.

In: Yonsei medical journal, Vol. 49, No. 3, 01.06.2008, p. 451-458.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A comprehensive prognostic stratification for patients with metastatic renal clear cell carcinoma

AU - Cho, Kang Su

AU - Choi, Young Deuk

AU - Kim, Se Joong

AU - Kim, Chun Il

AU - Chung, Byung Ha

AU - Seong, Do Hwan

AU - Lee, Dong Hyeon

AU - Cho, Jin Seon

AU - Cho, In Rae

AU - Hong, Sung Joon

PY - 2008/6/1

Y1 - 2008/6/1

N2 - Purpose: To develop a reliable prognostic model for patients with metastatic renal cell carcinoma (RCC) based on features readily available in common clinical settings. Patients and Methods: A total of 197 patients with RCC who underwent nephrectomy and immunotherapy from 1995 to 2004 were retrospectively reviewed. Their mean age was 55.1 ± 11.8 yrs (24-83 yrs) and mean survival time from metastasis was 22.6 ± 20.2 mos (3-120 mos). The impact of 24 clinicopathological features on disease specific survival was investigated. Results: On univariate analysis, constitutional symptoms, sarcomatoid differentiation, tumor necrosis, multiple primary lesions, liver metastasis, Eastern Cooperative Oncology Group Performance Status (ECOG-PS), thrombocytosis, alkaline pbosphatase, hematocrit, T stage, N stage, and nuclear grade had significant influence on survival (p < 0.05). Multivariate analysis revealed the following features associated with survival: sarcomatoid differentiation [hazard ratio (HR)=2.99, p<0.001], liver metastasis (HR = 2.09, p = 0.002), ECOG-PS (HR = 1.95, p = 0.005), N stage (HR = 1.94, p = 0.002), and number of metastatic sites (HR = 1.76, p = 0.003). An individual prognostic score was defined as the sum of the weight of these features. According to prognostic scores, patients could be subdivided into 3 groups: low risk (score 0), intermediate risk (score 1 or 2), and high risk (score ≥ 3). Conclusion: A comprehensive prognostic stratification model was developed to predict survival and stratify patients for prospective clinical trials.

AB - Purpose: To develop a reliable prognostic model for patients with metastatic renal cell carcinoma (RCC) based on features readily available in common clinical settings. Patients and Methods: A total of 197 patients with RCC who underwent nephrectomy and immunotherapy from 1995 to 2004 were retrospectively reviewed. Their mean age was 55.1 ± 11.8 yrs (24-83 yrs) and mean survival time from metastasis was 22.6 ± 20.2 mos (3-120 mos). The impact of 24 clinicopathological features on disease specific survival was investigated. Results: On univariate analysis, constitutional symptoms, sarcomatoid differentiation, tumor necrosis, multiple primary lesions, liver metastasis, Eastern Cooperative Oncology Group Performance Status (ECOG-PS), thrombocytosis, alkaline pbosphatase, hematocrit, T stage, N stage, and nuclear grade had significant influence on survival (p < 0.05). Multivariate analysis revealed the following features associated with survival: sarcomatoid differentiation [hazard ratio (HR)=2.99, p<0.001], liver metastasis (HR = 2.09, p = 0.002), ECOG-PS (HR = 1.95, p = 0.005), N stage (HR = 1.94, p = 0.002), and number of metastatic sites (HR = 1.76, p = 0.003). An individual prognostic score was defined as the sum of the weight of these features. According to prognostic scores, patients could be subdivided into 3 groups: low risk (score 0), intermediate risk (score 1 or 2), and high risk (score ≥ 3). Conclusion: A comprehensive prognostic stratification model was developed to predict survival and stratify patients for prospective clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=48649083951&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48649083951&partnerID=8YFLogxK

U2 - 10.3349/ymj.2008.49.3.451

DO - 10.3349/ymj.2008.49.3.451

M3 - Article

C2 - 18581596

AN - SCOPUS:48649083951

VL - 49

SP - 451

EP - 458

JO - Yonsei Medical Journal

JF - Yonsei Medical Journal

SN - 0513-5796

IS - 3

ER -